{"disease":{"id":"refractory","name":"refractory"},"drugs":{"marketed":[{"drug_id":"vedolizumab","indication_name":"Chronic antibioticrefractory ileal pouchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Entyvio","generic_name":"vedolizumab","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Integrin alpha-4/beta-7","drug_class":"Integrin Receptor Antagonist [EPC]","quality_score":10,"revenue":"7300","mechanism":"Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue."},{"drug_id":"upadacitinib","indication_name":"Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"olaparib","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"polatuzumab-vedotin","indication_name":"Diffuse large B-cell lymphoma refractory","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Polivy","generic_name":"POLATUZUMAB VEDOTIN","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-cell antigen receptor complex-associated protein beta chain","drug_class":"","quality_score":66,"revenue":"1600","mechanism":"Polivy works by binding to a protein on the surface of cancer cells and releasing a toxin that kills the cell."},{"drug_id":"darolutamide","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"nivestym","indication_name":"Refractory acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"ciltacabtagene-autoleucel","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":"1100","mechanism":null},{"drug_id":"ciltacabtagene-autoleucel","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":"1100","mechanism":null},{"drug_id":"burosumab","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crysvita","generic_name":"BUROSUMAB","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"FGF23","drug_class":"","quality_score":62,"revenue":"700","mechanism":"Burosumab-twza binds to and inhibits FGF23, restoring renal phosphate reabsorption and increasing 1,25 dihydroxy vitamin D levels."},{"drug_id":"niraparib","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zejula","generic_name":"niraparib","company_name":"GSK","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":69,"revenue":"600","mechanism":"Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells."},{"drug_id":"roxadustat","indication_name":"Refractory anemia (clinical)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrenzo","generic_name":"ROXADUSTAT","company_name":"Astellas Pharma Europe B.V.","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"","quality_score":35,"revenue":"600","mechanism":""},{"drug_id":"teclistamab","indication_name":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"teclistamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"talquetamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talvey","generic_name":"TALQUETAMAB","company_name":"Janssen Biotech ","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"","quality_score":63,"revenue":"400","mechanism":"Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells."},{"drug_id":"teclistamab","indication_name":"Relapsed or Refractory Multiple Myeloma (Monotherapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"elrexfio","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrexfio","generic_name":"Elranatamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells","drug_class":"Bispecific antibody","quality_score":10,"revenue":"304","mechanism":"Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis."},{"drug_id":"elranatamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrexfio","generic_name":"elranatamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells","drug_class":"Bispecific antibody","quality_score":74,"revenue":"304","mechanism":"Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis."},{"drug_id":"elranatamab-bcmm","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrexfio","generic_name":"elranatamab-bcmm","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17","drug_class":"","quality_score":68,"revenue":"304","mechanism":"Elrexfio works by binding to tumor necrosis factor receptor superfamily member 17, a protein involved in the growth and survival of cancer cells."},{"drug_id":"glofitamab","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Columvi","generic_name":"glofitamab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","quality_score":79,"revenue":"300","mechanism":"Columvi works by binding to the CD20 protein on B-cell lymphoma cells, triggering an immune response to destroy the cancer cells."},{"drug_id":"belantamab-mafodotin","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenrep","generic_name":"BELANTAMAB MAFODOTIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"BCMA","drug_class":"","quality_score":63,"revenue":"300","mechanism":"Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"chembl-chembl2108611","indication_name":"Relapsed or Refractory CD22+ B-cell Precursor ALL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"INOTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":61,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate that binds to CD22 on tumor cells, internalizes, and releases a cytotoxic agent causing DNA damage and cell death."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"tafasitamab","indication_name":"Diffuse large B-cell lymphoma refractory","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xmab5574","generic_name":"tafasitamab","company_name":"Morphosys Us Inc","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":null,"revenue":"100","mechanism":"Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells."},{"drug_id":"gemtuzumab-ozogamicin","indication_name":"Relapsed or refractory CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"gemtuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"100","mechanism":"Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells."},{"drug_id":"gemtuzumab","indication_name":"relapsed or refractory CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 19 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Polycythemia vera (PV) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 27 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 28 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 29 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 30 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 31 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 32 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 33 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 19 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 20 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 21 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 22 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 23 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 24 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 25 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 26 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 34 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 35 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 36 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 37 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 38 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 39 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 40 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 41 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 42 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 43 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 44 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 45 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 46 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 47 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 48 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 49 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 50 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 51 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 52 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 53 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 54 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 55 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 56 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 57 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 58 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 59 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 60 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 61 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 62 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 63 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 64 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 65 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 66 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 67 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 68 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 69 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 70 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 71 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 72 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 73 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 74 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 75 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 76 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 77 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 78 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 79 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 80 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 81 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 82 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 83 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 84 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 85 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 86 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 87 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 88 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 89 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 90 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 91 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 92 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 93 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 94 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 95 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 96 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"caspofungin","indication_name":"Refractory Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cancidas","generic_name":"CASPOFUNGIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":63,"revenue":null,"mechanism":"Cancidas works by inhibiting the synthesis of beta-1,6-glucan, a critical component of the fungal cell wall."},{"drug_id":"valemetostat","indication_name":"Relapsed or refractory T-cell leukemia-lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ezharmia","generic_name":"VALEMETOSTAT","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Histone-lysine N-methyltransferase EZH2","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"neupogen","indication_name":"Refractory acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"polatuzumab","indication_name":"Diffuse large B-cell lymphoma refractory","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Polatuzumab","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"B-cell antigen receptor complex-associated protein beta chain, Tubulin beta","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"azathioprine","indication_name":"Refractory autoimmune haemolytic anaemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Refractory idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"glimepiride","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"rosiglitazone","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avandia","generic_name":"ROSIGLITAZONE","company_name":"Woodward","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 1","drug_class":"Peroxisome Proliferator Receptor gamma Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Refractory Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"bendamustine","indication_name":"Diffuse large B-cell lymphoma refractory","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"gefapixant-citrate","indication_name":"Refractory chronic cough","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyfnua","generic_name":"GEFAPIXANT CITRATE","company_name":"Msd K.K.","drug_phase":"marketed","molecular_target":"P2X purinoceptor 3","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Waldenström Macroglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mycosis Fungoides","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Sézary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Waldenström Macroglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mycosis Fungoides","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Sézary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Waldenström Macroglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mycosis Fungoides","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Sézary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Waldenström Macroglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mycosis Fungoides","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Sézary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Waldenström Macroglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mycosis Fungoides","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Sézary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Waldenström Macroglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Hairy Cell Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Cutaneous T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mycosis Fungoides","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Sézary Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Peripheral T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory T-Cell Large Granular Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Marginal Zone Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"metformin","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"linvoseltamab","indication_name":"relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynozyfic","generic_name":"LINVOSELTAMAB","company_name":"Rengeneron Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC]","quality_score":52,"revenue":null,"mechanism":"Lynozyfic works by binding to specific cells involved in multiple myeloma."},{"drug_id":"linvoseltamab","indication_name":"relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynozyfic","generic_name":"LINVOSELTAMAB","company_name":"Rengeneron Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC]","quality_score":52,"revenue":null,"mechanism":"Lynozyfic works by binding to specific cells involved in multiple myeloma."},{"drug_id":"allr3","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory follicular lymphoma after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory mantle cell lymphoma (MCL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory small lymphocytic lymphoma (SLL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"elrantamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrantamab","generic_name":"elrantamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen)","drug_class":"Bispecific Antibody","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"pf-07248144","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"melflufen","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Melflufen","company_name":"Oncopeptides AB","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"pf-07264660","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07264660","generic_name":"pf-07264660","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":34,"revenue":null,"mechanism":"The mechanism of action of PF-07264660 is not specified."},{"drug_id":"pf-07293893","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"campath","indication_name":"Refractory chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eculizumab","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"calciferol","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"glucophage","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"burosumab-twza","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CRYSVITA","generic_name":"BUROSUMAB-TWZA","company_name":"KYOWA KIRIN","drug_phase":"marketed","molecular_target":"Fibroblast growth factor 23","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"tafasitamab-cxix","indication_name":"Diffuse large B-cell lymphoma refractory","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MONJUVI","generic_name":"TAFASITAMAB-CXIX","company_name":"MORPHOSYS US INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD19","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"mosunetuzumab-axgb","indication_name":"Relapsed or refractory follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LUNSUMIO","generic_name":"MOSUNETUZUMAB-AXGB","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"glofitamab-gxbm","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"COLUMVI","generic_name":"GLOFITAMAB-GXBM","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3 epsilon chain","drug_class":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"talquetamab-tgvs","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TALVEY","generic_name":"TALQUETAMAB-TGVS","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"G-protein coupled receptor family C group 5 member D, T-cell surface glycoprotein CD3","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"pf-07284892","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284892","generic_name":"pf-07284892","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"oral-pf-07220060","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral PF-07220060","generic_name":"oral-pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"loncastuximab","indication_name":"relapsed or refractory large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynlonta","generic_name":"LONCASTUXIMAB","company_name":"ADC Therapeutics SA","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction."},{"drug_id":"lynparza","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"chidamide","indication_name":"Relapsed or refractory T-cell leukemia-lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chidamide","company_name":"Sun Yat-sen University","drug_phase":"phase_3","molecular_target":"Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"baraclude","indication_name":"Lamivudine-Refractory Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Baraclude","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Capsid protein, Protein P, Protein P","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"epcoritamab","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epkinly","generic_name":"EPCORITAMAB","company_name":"Genmab Us, Inc.","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"Bispecific CD20-directed CD3 T Cell Engager [EPC]","quality_score":10,"revenue":null,"mechanism":"Epkinly works by binding to the T-cell surface glycoprotein CD3, which is a key component of the T-cell receptor complex."},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 19 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 20 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 21 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 22 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 23 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 24 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 25 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 26 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 27 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 28 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 29 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 30 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 31 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 32 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 33 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 34 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 35 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 36 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 37 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 38 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 39 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 40 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 41 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 42 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 43 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 44 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 45 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 46 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 47 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 48 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 49 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 50 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 51 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 52 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 53 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 54 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 55 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 56 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 57 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 58 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 59 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 60 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 61 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 62 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 63 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 64 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 65 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 66 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 67 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 68 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 69 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 70 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 71 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 72 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 73 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 74 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 75 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 76 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 77 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 78 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 79 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 80 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 81 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 82 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 83 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 84 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 85 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 86 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 87 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 88 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 89 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 90 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 91 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 92 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 93 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 94 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 95 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 96 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 97 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 98 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 99 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 100 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 101 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 102 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 103 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"nipent","indication_name":"Alpha-interferon-refractory hairy cell leukemia with active disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nipent","generic_name":"Pentostatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Adenosine deaminase (ADA)","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"entecavir","indication_name":"Lamivudine-Refractory Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baraclude","generic_name":"ENTECAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"entecavir","quality_score":70,"revenue":null,"mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory advanced follicular lymphoma (FL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"melphalan-flufenamide","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepaxto","generic_name":"MELPHALAN FLUFENAMIDE","company_name":"Oncopeptides Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"mosunetuzumab","indication_name":"Relapsed or refractory follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lunsumio","generic_name":"MOSUNETUZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"e7777","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontak","generic_name":"E7777","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"CD25-directed Cytotoxin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alemtuzumab","indication_name":"Refractory chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"denileukin-diftitox","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontak","generic_name":"DENILEUKIN DIFTITOX","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"CD25-directed Cytotoxin [EPC]","quality_score":10,"revenue":null,"mechanism":"Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells."},{"drug_id":"darinaparsin","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darvias","generic_name":"DARINAPARSIN","company_name":"Solasia Pharma K.K","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Darvias works by inhibiting the enzyme glutathione S-transferase pi (GSTP1), which is involved in the cell's detoxification process."},{"drug_id":"olutasidenib","indication_name":"Refractory acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"bendamustin","indication_name":"Diffuse large B-cell lymphoma refractory","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ontak","indication_name":"Refractory peripheral T-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ontak","company_name":"The University of Texas Health Science Center at San Antonio","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"soliris","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"epcoritamab-bysp","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EPKINLY","generic_name":"EPCORITAMAB-BYSP","company_name":"GENMAB US, INC.","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma with EZH2 Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma without Satisfactory Alternatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"azacitidine","indication_name":"Refractory Anemia (RA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"azacitidine","indication_name":"Refractory Anemia with Ringed Sideroblasts (RARS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"azacitidine","indication_name":"Refractory Anemia with Excess Blasts (RAEB)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"azacitidine","indication_name":"Refractory Anemia with Excess Blasts in Transformation (RAEB-T)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"denileukin-diftitox-cxdl","indication_name":"Relapsed or Refractory CTCL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LYMPHIR","generic_name":"DENILEUKIN DIFTITOX-CXDL","company_name":"CITIUS PHARMS","drug_phase":"marketed","molecular_target":"","drug_class":"CD25-directed Cytotoxin [EPC]","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or Refractory Multiple Myeloma (Monotherapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"naxitamab","indication_name":"Relapsed or Refractory High-Risk Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu3F8","generic_name":"NAXITAMAB","company_name":"Y-Mabs Therapeutics Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":53,"revenue":null,"mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system."},{"drug_id":"mitoxantrone","indication_name":"Advanced Hormone-Refractory Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"chembl-chembl3655081","indication_name":"Refractory, moderate-to-severe atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ABROCITINIB","company_name":"","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"CIBINQO works by reversibly inhibiting JAK1, blocking ATP binding and showing selectivity over other JAKs."},{"drug_id":"chembl-chembl1201576","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201506","indication_name":"Relapsed or refractory CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEMTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl941","indication_name":"Relapsed/Refractory Ph+ ALL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl44657","indication_name":"Refractory Testicular Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ETOPOSIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1489","indication_name":"Refractory Anemia (RA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1489","indication_name":"Refractory Anemia with Ringed Sideroblasts (RARS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1489","indication_name":"Refractory Anemia with Excess Blasts (RAEB)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1489","indication_name":"Refractory Anemia with Excess Blasts in Transformation (RAEB-T)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545131","indication_name":"Relapsed or Refractory Multiple Myeloma (1-3 prior therapies)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl11359","indication_name":"Metastatic Ovarian Tumors - Refractory to Standard Chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISPLATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Platinum-based Drug [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"intravesical-solution","indication_name":"BCG-refractory CIS of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravesical Solution","company_name":"Ankara Training and Research Hospital","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Platinum-resistant/refractory high-grade serous ovarian cancer","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Relapsed/refractory metastatic breast cancer (in combination with vorinostat)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."}],"offLabel":[],"totalMarketed":628,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01321567","title":"Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis","phase":"","overall_status":"COMPLETED","enrollment_count":2157,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT03327571","title":"B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06825845","title":"Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"CARsgen Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT03301493","title":"Genomic Testing and Resulting Medical Decisions","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT00286091","title":"Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1435,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05455606","title":"Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1284,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT00900250","title":"Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":1271,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02224755","title":"MOMENTUM 3 IDE Clinical Study Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":1028,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT05713214","title":"Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05600777","title":"A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":975,"lead_sponsor_name":"Bellus Health Inc. - a GSK company","has_results":false},{"nct_id":"NCT00699751","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":921,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT07222761","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":915,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06285318","title":"A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT05455320","title":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":864,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05599191","title":"A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":825,"lead_sponsor_name":"Bellus Health Inc. - a GSK company","has_results":false},{"nct_id":"NCT05519085","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":810,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02613962","title":"Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling","phase":"NA","overall_status":"COMPLETED","enrollment_count":791,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT03169361","title":"NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) \"Relapsed/Refractory Multiple Myeloma\"","phase":"","overall_status":"COMPLETED","enrollment_count":774,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02960763","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05693831","title":"myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports","phase":"","overall_status":"UNKNOWN","enrollment_count":730,"lead_sponsor_name":"Cellworks Group Inc.","has_results":false},{"nct_id":"NCT01564537","title":"A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05572515","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":614,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04224493","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":612,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT03257267","title":"Study of Cemiplimab in Adults With Cervical Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05552976","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":606,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05270096","title":"International Leukemia Target Board","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false},{"nct_id":"NCT04496310","title":"Tele-epic (Telemedicine for Epilepsy Care)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Azienda Usl di Bologna","has_results":false},{"nct_id":"NCT01787409","title":"Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06202417","title":"Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study","phase":"","overall_status":"COMPLETED","enrollment_count":520,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT07391657","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02500043","title":"Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":507,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT05970081","title":"Effectiveness and Safety of Implantable Intrathecal Systems for Refractory Pain in Spain (INTRATHECAL-RENASED)","phase":"","overall_status":"UNKNOWN","enrollment_count":504,"lead_sponsor_name":"Sociedad Espanola del Dolor","has_results":false},{"nct_id":"NCT05556642","title":"Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT04587388","title":"Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"European Hematology Association - Lymphoma Group","has_results":false},{"nct_id":"NCT04737187","title":"Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":492,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT06952478","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"Celltrion","has_results":false},{"nct_id":"NCT04712097","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":478,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06149286","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03158688","title":"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":466,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07383779","title":"Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":466,"lead_sponsor_name":"Versailles Hospital","has_results":false},{"nct_id":"NCT06196723","title":"Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites","phase":"","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT00114101","title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":460,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06504446","title":"Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":455,"lead_sponsor_name":"Nocion Therapeutics","has_results":false},{"nct_id":"NCT03859427","title":"A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04921527","title":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"Chipscreen Biosciences, Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}